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Abstract
Background: G-DOC Plus is a data integration and bioinformatics platform that uses cloud computing and other
advanced computational tools to handle a variety of biomedical BIG DATA including gene expression arrays, NGS
and medical images so that they can be analyzed in the full context of other omics and clinical information.
Results: G-DOC Plus currently holds data from over 10,000 patients selected from private and public resources
including Gene Expression Omnibus (GEO), The Cancer Genome Atlas (TCGA) and the recently added datasets from
REpository for Molecular BRAin Neoplasia DaTa (REMBRANDT), caArray studies of lung and colon cancer, ImmPort
and the 1000 genomes data sets. The system allows researchers to explore clinical-omic data one sample at a time,
as a cohort of samples; or at the level of population, providing the user with a comprehensive view of the data.
G-DOC Plus tools have been leveraged in cancer and non-cancer studies for hypothesis generation and validation;
biomarker discovery and multi-omics analysis, to explore somatic mutations and cancer MRI images; as well as for
training and graduate education in bioinformatics, data and computational sciences. Several of these use cases are
described in this paper to demonstrate its multifaceted usability.
Conclusion: G-DOC Plus can be used to support a variety of user groups in multiple domains to enable hypothesis
generation for precision medicine research. The long-term vision of G-DOC Plus is to extend this translational
bioinformatics platform to stay current with emerging omics technologies and analysis methods to continue
supporting novel hypothesis generation, analysis and validation for integrative biomedical research. By integrating
several aspects of the disease and exposing various data elements, such as outpatient lab workup, pathology,
radiology, current treatments, molecular signatures and expected outcomes over a web interface, G-DOC Plus will
continue to strengthen precision medicine research. G-DOC Plus is available at: https://gdoc.georgetown.edu.
Keywords: Bioinformatics, Translational research, Precision medicine, Cloud computing, Variant analysis, Next
generation sequencing, Outcomes research, Genotype-phenotype integration
Background
The advent of the microarray technology in the year
2000 has paved the way for advanced translational re-
search methods that have helped biologists analyze large
group of genes as opposed to looking at one gene at a
time. These methods have also been extended to other
molecular markers such as microRNA, proteins, metab-
olites and DNA copy number data. Our flagship web
platform, the Georgetown Database of Cancer (G-DOC)
[1] was developed and deployed in April 2011 to enable
the practice of an integrative translational and systems-
based approach to research and medicine in cancer. G-
DOC is a feature-rich shareable research infrastructure
that allows physician scientists and translational re-
searchers to mine and analyze a variety of “omics” data
in the context of consistently defined clinical outcomes
data for cancer patients.
This paradigm shift of looking at a group of markers
has driven the development of next generation sequen-
cing (NGS) platforms to analyze biological samples. The
popularity of NGS grew exponentially since 2007 when
faster, more accurate and affordable sequencing through-
put became a reality [2, 3]. Since then, the size and
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complexity of genomic data has increased many fold,
making its analysis, management and integration in-
creasingly challenging [3].
Scientists today are using not only a combination of
clinical, NGS and omics data for analysis, but also
medical and digital images for validation of analysis re-
sults. Currently, numerous tools and software exist that
specialize in the handling and processing of one or two
“omics” data types, or only NGS data. Many of these sys-
tems require a bioinformatician to help with analysis. To
drive hypothesis generation and validation of molecular
markers for biologists and researchers, it would be con-
venient to have a “one-stop” system that can handle all
of these data types, including NGS and medical images,
in one location without having to switch to other tools
or resources for analysis. For this purpose, we expanded
the G-DOC system to support NGS and medical images.
Moreover, the success of G-DOC in the cancer realm
has helped us realize the importance of such systems in
the non-cancer world for complex diseases including
Alzheimer’s, and Duchene Muscular Dystrophy (DMD).
With the goal of improving overall health outcomes
through genomics research, we present G-DOC Plus, a
web-based bioinformatics platform that enables the inte-
grative analysis of multiple data types to understand
mechanisms of cancer and non-cancer diseases at a sys-
tems level for systematic conduct of research in preci-
sion medicine. G-DOC Plus currently holds data from
over 10,000 patients selected from private and public re-
sources including Gene Expression Omnibus (GEO),
The Cancer Genome Atlas (TCGA) and the recently
added datasets from REpository for Molecular BRAin
Neoplasia DaTa (REMBRANDT), caArray studies of lung
and colon cancer and the 1000 genomes data sets. G-
DOC Plus allows researchers to explore clinical-omic
data one sample at a time, as a cohort of samples; or at
the level of population, providing the user with a com-
prehensive view of the data.
Implementation
Data
All data in G-DOC Plus are organized as “studies” on
topics such as breast cancer, wound healing, or the 1000
Genomes project. Each study may contain de-identified
clinical and biospecimen data, including mRNA and
miRNA expression, copy number variation, metabolite
mass spectrometry data; whole genome sequencing
(WGS) data and medical images, currently adding to
over 10000 patient and cell line datasets.
The data collection includes WGS data from the 1000
Genomes Project [4] and Complete Genomics [5]; multi-
omics data from the NCI-60 data collection; numerous
breast, GI, and pediatric cancer studies; and non-cancer
studies including Duchenne muscular dystrophy (DMD)
and Alzheimer’s disease from public resources including
Gene expression Omnimus (GEO) [6] and TCGA [7].
In March 2015, data from REpository for Molecular
BRAin Neoplasia DaTa (REMBRANDT) portal [8] (http://
rembrandt.nci.nih.gov), and two studies from Ca Array [9]
were migrated to G-DOC Plus. Most recently, two Infec-
tious Disease (ID) studies were added to our data collec-
tion, one of which is from the Immunology Database and
Analysis Portal (ImmPort) data collection [10].
A summary of G-DOC Plus data management and
analysis features is shown in Fig. 1, and a summary of
currently available data collection can be seen on the front
page of the software system at https://gdoc.georgetown.edu,
also shown in Additional file 1.
Tools and features
G-DOC Plus has three inter-connected entry points for
the user based on their interests: (1) Precision Medicine
workflow that allows researchers to explore data one
sample at a time, (2) Translational Research workflow al-
lows exploring data as a sub-cohort of samples and (3)
Population Genetics workflow allows uses to look a popu-
lation as a whole. This provides users with a comprehen-
sive view of the data and facilitates hypothesis generation
for basic, clinical, and translational researchers.
G-DOC Plus has a broad collection of tools that are
summarized in the form of a schematic diagram in Fig. 2.
It includes differential expression analysis, heat maps
and hierarchical clustering, principal component analysis
(PCA), survival analysis (Kaplan-Meier), tools to view
copy number instability, interaction networks in Cytos-
cape, molecular targets; and a genome browser. It also
includes a number of recently added tools including
pathway enrichment (using Reactome database [11]) and
tools to explore germline and somatic mutations and
medical MRI images.
System architecture
G-DOC Plus uses an in-house architectural framework
that provides over 1500 biomedical research users (as of
March 2016) with a comprehensive set of analysis rou-
tines and visualizations for a rich user experience
through a web interface. The data and meta-data are
stored in an Oracle database that allows for access con-
trol. The G-DOC Plus application is written in Groovy
& Grails, an open source application framework that
runs on the Java Virtual Machine (JVM) that is built on
top of libraries such as Spring and Hibernate that meet
high industry standards. This provides for a highly struc-
tured web application framework and allows for rapid
development of modules. Adobe Flex and Javascript are
used to provide interactive data visualizations. The sys-
tem uses JBossMQ to communicate asynchronously with
an analysis server on which analysis routines (such as
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Fig. 1 Summary of G-DOC Plus data management and analysis features
Fig. 2 Summary of G-DOC Plus tools under each workflow
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classification, hierarchical clustering, etc.) are run using
R/Bioconductor packages [12].
This architecture has since been expanded in G-
DOC Plus to allow storage and analysis of NGS data
and medical images by using EC2 instances [13] in the
Amazon cloud computing environment [14]. These
compute intensive instances offer the ability to rapidly
scale in the face of a deluge of data at a very low main-
tenance cost.
Genomic data by its very nature is very complex and
subject to changes due to rapidly changing knowledge
and technologies in the field of genomics. Traditional
SQL databases require highly structured and well-
defined data and are not flexible enough to handle such
rapid changes. For large hierarchical datasets such as
NGS, transactions on relational databases can be very
expensive [15]. NoSQL [16] databases such as MongoDB
[17] are best suited for such applications. They lack the
rigorous consistencies of SQL in favor of rapid develop-
ment in the face of changing data. According to the
Consistency, Availability, and Partition tolerance (CAP)
theorem [18], these NoSQL databases tend to focus
more on availability and partition tolerance than
consistency (as opposed to SQL databases which focus
more on consistency). This makes them ideal for hous-
ing, indexing and retrieving big data.
We utilized MongoDB to store the variant data from
sequencing studies because of its inherent scalability and
high performance on very large data sets. This database
is located in an EC2 server instance on the Amazon
cloud. Each NGS dataset is stored as a “collection” [17].
The data are indexed so that data retrieval is fast and ef-
ficient. Every record in the database is a unique “docu-
ment” [19] in the form of BSON (binary JSON) objects
[20], and holds variant data and meta-data in the form
of key-value pairs. This JSON based data model allows
for adding new attributes such as annotation attributes
without changing the underlying database design. This
allows for a very flexible implementation that can be
changed as new annotation types emerge. The G-DOC
Plus web application layer executes queries against the
mongoDB database using web services that are exposed
by a Python based Django [21] application. This web ser-
vice crafts and parses the query, and extracts the results
for the end user.
The medical MRI images are in the form of standard
Digital Imaging and Communications in Medicine
(DICOM) objects [22]. In G-DOC Plus, the images are
stored in a DICOM Clinical Data Manager “Dcm4chee”
system. This system sits on a JBoss web application that
is hosted on an EC2 server instance on the Amazon
cloud. The meta- data of the images are stored in a
MySQL database, also located on the EC2 server.
The images along with its meta-data are archived
comprehensively within the Dcm4chee system to
allow for easy extraction and presentation in G-DOC
Plus. The EC2 server also contains Oviyam [23], a
cross platform DICOM viewer that was integrated to
enable web based access to the medical images. Both
Dcm4chee and Oviyam are open source tools and they
allow for exploration of medical images and associated
meta-data. The medical images are also linked to the
phenotypic data of the patient, which allows filtering
and selection of images for a specific patient based on
their clinical data.
Figure 3a shows an overview of the architecture, in-
cluding how the system interacts with the cloud in-
stances to retrieve NGS and medical images. As of
March 2016, the system hosts 82 GB of clinical and
other omics data, 152 GB of processed NGS data, 56 GB
of medical images and 720 MB of meta-data.
The G-DOC Plus ecosystem
The G-DOC Plus ecosystem is a generalized concept
that was realized for easy replication of the G-DOC Plus
tools for similar applications. It consists of many inde-
pendent “plugins” built on top of two base plugins to
form a comprehensive ecosystem. A plugin is an inde-
pendent lightweight “mini” grails project that cannot be
run on its own on a web server. Figure 3b shows the
plugins used in G-DOC Plus.
G-core is a ‘core’ grails plugin created and installed
into a skeleton grails application to provide a uniform
database schema, common security framework that in-
cludes authentication, authorization, registration and
basic features of a portal (exploring clinical data, sav-
ing patient lists, workflows). This is the biggest and
most important plugin, and in principle the G-DOC
application can be run with only the G-core plugin
without any other plugin. The analysis-core plugin is
another ‘core’ plugin developed to create communica-
tion between the analysis server and any type of ana-
lysis that requires computation. All plugins have a
dependency on g-core plugin and those that call the
analysis server are also dependent on the analysis-core
plugin. The primary analysis features are built as plu-
gins on top of these two base plugins, perform specific
tasks for data management or analysis, and are inde-
pendent of each other.
Such an ecosystem allows for easy creation of new plu-
gins based on new analyses requirements, and independ-
ent installation into any application that already has the
‘core’ plugins installed. This module-based system hence
gives us the flexibility to pick the necessary plugins to be
able to build a G-DOC like web portal for another col-
laborator/application.
All source code for G-DOC Plus is available in Github
[24]. It is currently a private repository and can be freely
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shared with academic collaborators or developers after
establishing a Memorandum of Understanding (MOU)
with Georgetown University.
Results and discussion
As described previously, The Georgetown Database of
Cancer (G-DOC) was developed and deployed 5 years
ago; at that time, it contained only cancer datasets and
tools to handle multi-omics data. The goal was to enable
a translational and systems-based approach to research
and medicine in cancer. The tools available in the system
at the time are now part of the “Translational Research”
module in G-DOC Plus.
The success of G-DOC in the cancer realm helped
us realize the importance of such systems in the
non-cancer world for complex diseases including
Alzheimer’s, and Duchene Muscular Dystrophy (DMD).
Scientists today are using not only clinical and targeted
omics data, but also Next Generation Sequencing
(NGS) data, medical and digital images for a variety of
analysis. To drive hypothesis generation and validation
of molecular markers for biologists and researchers, it
would be convenient to have a “one-stop” system that
can handle various data types, including NGS and med-
ical images, in one location without having to switch to
other tools or resources for analysis. For these reasons,
we significantly expanded the G-DOC system to include
non-cancer datasets and newer data types (hence the
name G-DOC “Plus”).
Apart from our cancer datasets collection, G-DOC
Plus currently includes data on various non-cancer
diseases including Dementia, DMD and Wound healing.
We are continuing to enrich this collection and most
recently added two Infectious disease datasets.
In addition to the Translational research module, G-
DOC Plus includes two new modules –Precision
medicine and Population genetics modules. To enable
use cases in these additional modules, new tools (“Va-
riant Search”, “Explore Medical Images”, “Phenotype
Search”), and datasets were added to the system (NGS
data from The 1000 Genomes project and Complete
Genomics Breast Cancer dataset; and TCIA MRI im-
aging data).
The overall user interface was redesigned to provide
better end user experience in G-DOC Plus. Also, the
web interface of the menu option: “Explore clinical data
and create groups” (the clinical data exploratory tool)
was upgraded with a new user-friendly interface that
offered total counts for each combination of variables
selected. In addition, the backend architecture was re-
designed into a modular structure (Grails plugin architec-
ture) allowing for a flexible and extendible framework
for new analysis modules to be easily added to the plat-
form. Another enhancement to the architecture allows for
whole genome sequencing (WGS) data and the MRI
images to be stored on a cloud infrastructure.
We have continued to improve our cancer data collec-
tion by adding new datasets including three large data
Fig. 3 a General system architecture of G-DOC Plus. b Summary of plugins in G-DOC Plus. The plugins marked in * indicate open source plugins
that were customized for G-DOC Plus
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collections transitioned from NCI to G-DOC Plus: the
REMBRANDT brain cancer dataset, Colon cancer and
Lung Cancer datasets (both from NCI caArray platform)
as well as NCI-60 cell line collection and Pediatric
cancer datasets.
A comprehensive table summarizing the differences
between G-DOC Plus and G-DOC has been provided in
Additional file 2.
G-DOC Plus can be used to support a variety of user
groups in multiple domains to enable hypothesis gen-
eration for precision medicine research. The tools in
G-DOC Plus have been leveraged to support numerous
case studies, some of which are described below to
demonstrate its multifaceted usability.
Case study 1: drug metabolizer status search
Common variants in the CYP family cause modified
drug function, and these variants are known to differ
greatly by ethnicity. Patients are classified into groups
referred to as “drug metabolizer status” or “pheno-
type” based on their modified drug function. These
groups are: (a) Ultra Rapid Metabolizers (UM) - have
5–6 copies of the variant (due to gene amplification)
that have a high response to the drug (b) Extensive
Metabolizers (EM) – Have two copies of the variant
and have a normal response to the drug (c) Inter-
mediate Metabolizers (IM) - Have one copy of variant
and have a medium response to the drug and (d) Poor
Metabolizers (PM) – have both copies of the variant
deleted and have low response or adverse effect to the
drug [25].
This use case involved understanding racial/ethnic
distribution of dysfunctional genotypes and genotype-
derived phenotypes (i.e., haplotypes) for absorption, dis-
tribution, metabolism and excretion (ADME) related
genes. To enable this, we integrated public genome data
from the 1000 genomes project [4] with data from the
Affymetrix Drug Metabolizing Enzymes and Trans-
porter (DMET) console [26] and calculated the haplo-
types and phenotype (drug metabolizer status) for the
ADME genes. Out of ~2000 ADME genes, metabolizer
status information was available for 20 genes. Variations
were found in 19 of the 20 genes for at-least one person
in the dataset. The frequency of the drug metabolizer
status was then calculated for each of the five super
populations in the dataset for each gene. The druggabil-
ity of the gene was obtained from Sophic Alliance’s
Druggable Genome Database [27]. The steps used in the
data processing of this workflow for G-DOC Plus is
shown in Fig. 4. This pharmacogenomics (PGx) work-
flow allows the user to perform searches and filter re-
sults using gene, dbSNP id [28] or drug metabolizer
status.
Example query: How common is the “poor metabolizer”
phenotype in CYP2C19 in the 1000 genomes dataset?
CYP2C19 is known to be involved in clopidogrel (Plavix)
metabolism, and the activity of the drug depends on the
active metabolite. Users can query the G-DOC Plus
interface to see the frequency of PMs and UMs in the
1000 genomes dataset, which has been summarized in
Table 1. We saw that most of the poor and intermediate
metabolizers in this dataset were East Asians, which is
consistent with literature [29–31]. On the other hand, ma-
jority of the ultra rapid and extreme metabolizers were
Europeans and Africans. A screen shot of this on G-DOC
Plus is shown in Additional file 3.
Such a resource can help a researcher query the inter-
face to assess if a given ADME gene(s) is polymorphic
or not; or extract the racial/ethnic distribution of
metabolizer status for a gene of interest. This informa-
tion can be used (a) to assess whether an individual
with a SNP of interest will have efficacy to a drug or not
(b) to help understand SNP population frequencies for
specific drug targets in new drug applications, which
can help inform broad applicability of a drug to differ-
ent populations. A new drug’s sponsor can evaluate all
relevant target variants in various subpopulations and
(c) to adjust drug dosage, as UMs may need a smaller
dose to get required efficacy compared to EMs; while
an alternative drug treatment may be recommended for
PMs [25].
In the future, we plan to extend this workflow to all
genes. This unique new tool created using public data
can be used to create genomic profiles for precision
medicine research with a broad range of applications in
pharmacogenomics.
Case study 2: exploratory analysis of germline and
somatic variations
Users can explore somatic and germline variants in can-
cer samples using the G-DOC system. The “variant
search” tool allows users to explore and filter mutations
based on genes, chromosomes, functional location (coding
sequence, intronic, downstream of gene, upstream of gene,
5′ UTR, 3′ UTR, non-coding UTR, intergenic), and exonic
function (Loss of stop, Premature stop, Insertion, Deletion,
Frameshift, Substitution, Possible splice variant, Possible
5′ splice variant).
The inactivation of tumor suppressor genes could be
caused by accumulation of mutations or, loss of hetero-
zygosity (LOH), causing progression of cancer [32, 33];
one such location is Chromosome 8, and abnormalities
in this chromosome have been reported in breast, colon
and other cancer [34, 35]. This led us to the Example
query: which genes are affected by novel deletions in
chromosome 8 with potential impact on protein func-
tion, and what major pathways might these genes be
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involved in? Is there a networked relationship be-
tween one or more of these impacted genes?
The dataset used for this query was WGS data on
breast cancer cell lines from Complete Genomics [36].
This data was processed and stored in Mongo DB on
the Amazon cloud.
To find the answer to this query, we chose the follow-
ing settings on the G-DOC Plus interface: Chromosome:
8; Functional Location: coding sequences; Exonic func-
tion: Non-synonymous, Deletion; and Variant Inclusion:
Novel; which resulted in a list of seven variants from
seven different genes (Additional file 4 shows a screen
shot of the G-DOC Plus web page with these settings).
We saved the gene list from this result and performed
pathway enrichment analysis in G-DOC Plus. Many
of the pathways enriched were related to processing of
pre-mRNA and mature mRNA, which are known to
potentially alter gene expression and in-turn turn tumor
suppressor genes off [37]. The top pathway “Inactivation
of CD42 and RAC” indicated that when such RNA pro-
cessing pathways are turned negative, it causes other
tumor pathways to go out of control. The saved gene list
was also used to create a Cytoscape [38] network from
within G-DOC Plus. This cytoscape network showed an-
notation with diseases and molecules based on Cancer
Gene Index [39] (Fig. 5a and b).
This case study shown on cell line data, which repre-
sents individual tumors can be applied on other patient
Fig. 4 The workflow used to extract information for the 1000 genomes dataset in G-DOC Plus. The pre-processed data was about 132 GB in size
and stored in Mongo DB on the Amazon cloud for quick and efficient data retrieval
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datasets to allow in-depth analysis of germline mutations
for individual patients based on NGS data. The variant
search tool also allows exploration of somatic variants
(variants present in tumor, but not in matched normal
sample).
Case study 3: perform multi-omics analysis
G-DOC Plus has recently enabled the detection of prog-
nostic markers using multi-omics data for relapse in
colorectal cancer samples [40]. To demonstrate this func-
tionality in G-DOC Plus, we present an example query
that compared patients with Astrocytoma (low grade
glioma) with those with Gliobastoma (GBM, high
grade glioma) in the NCI REMBRANDT study.
Only patients that had gene expression, copy number
and clinical data available were considered for this case
study. Additional file 5 shows a screen shot of this co-
hort selection within G-DOC Plus. We first applied a T-
test with FDR correction [41] to find 1692 differentially
expressed genes (DEGs) with p-value cut off of 0.0001
and fold change cut off of 1.5. The most down-regulated
gene RHOF was six fold under-expressed in the GBM
group compared to the Astrocytoma group. This gene
is known to be down regulated in GBM patients
through the over expression of their activators [42].
Similar changes in expression in another under-
expressed gene MLNR (5.9 fold down in GBM group)
were found in low-grade gliomas of Chinese patients
[43]. Among the other DEGs, were CYP4A11, TXN,
MYLK, previously shown to be to be over expressed,
and COL9A3 previously shown to be under-expressed
in high-grade gliomas respectively [43, 44]. A screen
shot of this comparative analysis is shown in Add-
itional file 6, and a heatmap of DEG expression values
is shown in Fig. 6a.
We also examined DNA copy number data for these
patients using the chromosomal instability tool in G-
DOC Plus. From comparison of copy number data be-
tween the two glioma types (Additional file 7), we found
a higher level of chromosomal instability in the Astro-
cytoma group in chromosome 8q arm (indicated by the
bright red colors). Aberrations in the 8q arm in Astro-
cytoma patients are known in literature [45–47]
(Fig. 6b). The list of differentially changed cytobands
(Additional file 7) also showed higher instability in
GBM compared to Astrocytoma in the 7p and 10q re-
gions. These 7p and 10q regions are known to be highly
amplified in GBM patients [48–51]. Higher genomic
Fig. 5 a and b Pathway enrichment and gene network in G-DOC Plus
Table 1 Summary of modified drug function for CYP2C19 by
ethnicity in the 1000 genomes dataset exported from G-DOC
















UM (*17/*17)a 2 6 0 5 0
UM or EM
(*1/*17)
16 23 2 29 0
EM 55 35 31 38 0
IM 23 22 54 19 0
PM (*2/*2,
*2/*3, *3/*3)
1 3 11 1 0
Not PM 3 9 2 8 0
IM or PM 0 1 0 0 0
Unknown/NA 0 1 0 0 0
TOTAL % 100 100 100 100 0
The table shows that about 11 % of the East Asians were PMs, ~ 3 %
Africans, and ~ 1 % Ad mixed Americans were PMs (row shown in bold
font). We can see the opposite trend for UM where ~ 5 % Europeans, ~
6 % of Africans, ~ 2 % of Ad-mixed Americans were UMs, none of the East
Asians were UMs (row marked with a)
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Fig. 6 (See legend on next page.)
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instability is also synonymous with aggressive pheno-
type especially in cancer.
Finally, we looked at the overall survival of these
patients using the Kaplan Meier survival plot (Fig. 6c)
feature in G-DOC Plus, which showed the expected re-
sult that patients with Astrocytoma (low grade glioma)
had better survival rates than those with GBM (high
grade glioma) with a p-value of less than 0.05 from log
rank test.
The CIN index algorithm [52] currently imple-
mented in G-DOC Plus summarizes both gains and
losses of copy number as an “instability” (referred to
as “overall CIN index”). As an upcoming feature in
G-DOC Plus, we plan to enable analysis of gains and
losses of copy number separately, in addition to
“overall CIN index”. This CIN module is available to
the public in Bioconductor (http://bioconductor.org/
packages/CINdex/).
This kind of platform can enable users to generate
new hypotheses from existing data. There is often an
added value in obtaining new insights into the etiology,
diagnosis, treatment, and prevention of diseases from re-
analyzing published datasets. G-DOC Plus can be used
to perform such in silico meta-analysis of disparate stud-
ies. An example of such an in silico analysis done on
three ER+ breast cancer studies in G-DOC Plus was
done as part of the NCI In Silico Research Centers of
Excellence Program [53].
Case study 4: explore medical images in conjunction with
clinical data
G-DOC Plus allows researchers and radiologists to ex-
plore medical images associated with clinical outcome
using the Digital Imaging and Communications in Medi-
cine (DICOM) format. We currently have a public breast
cancer imaging study obtained from The Cancer
Imaging Archive (TCIA) (cancerimagingarchive.net) [54]
in the system to allow users to explore this functionality.
This module allows investigators secure access to view
aggregate data, perform simple data analysis, and run ad
hoc queries across the data. Since the medical images on
the cloud are linked to the clinical data of the patient in
the Oracle database, it allows filtering and selection of
images for a specific patient based on their clinical data.
Users can explore view images of all performed proce-
dures for all or any patient(s); or select a patient(s) based
on specific clinical attributes in the study before viewing
the imaging metadata (Fig. 7a). This can help correlate
large data sets with radiology information and identify
specific patterns in the data.
In the future, we plan to add more imaging data from
many diseases including breast cancer and traumatic
brain injury (TBI). We also envision additional capabilities
to handle images that help visualize added chemicals
(e.g. diagnostic dyes) within blood vessels, allow labeling
of specific metabolites in real time, and vascularization of
tumors. Such an imaging module will allow users to
(See figure on previous page.)
Fig. 6 a Heat map comparing Astrocytoma and GBM patients. Over-expression of genes in the heat map is represented in red color, and under-
expression is shown in green color. b Chromosome instability in chromosome 8. Here, black color indicates normal DNA copy number (i.e. no
instability); and the red color indicates instability - higher the instability, the brighter the red color on the heatmap. c Kaplan Meier survival plot
between Astrocytoma (red line) and Glioblastoma patients (blue line)
Fig. 7 a Selection of medical images based on clinical data of patient(s). b Screen shot of the medical MRI imaging module in G-DOC Plus
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conduct a comprehensive serial analysis of integrated
clinical, imaging, molecular, and genetic data from patient
cohorts. Figure 7b shows a screen shot of this module.
G-DOC Plus as a tool for in-silico confirmation of lab results
An increasing number of journals are asking biologists
to confirm their findings using well-known public studies
(such as TCGA, 1000 genomes) as part of validation of
their results. Many biologists have approached our group
at Georgetown-ICBI (Innovation Center for Biomedical
Informatics) with results from their lab to seek our help in
finding supporting evidence for confirmation of their lab
findings in publicly available studies. We use a number of
tools for this, including cBio portal [55], G-DOC and
Oncomine [56]. We have worked with scientific collabora-
tors in the breast and liver cancer areas and have been able
to confirm lab findings using public studies in G-DOC as
demonstrated in these publications [57–59].
G-DOC Plus has also been used by researchers for
new hypothesis generation and for finding suitable
datasets for their analysis as shown in these publica-
tions [60, 61].
G-DOC Plus for education and the community
Since 2012, G-DOC and its newer version G-DOC Plus
have been used as a hands-on tool to train scientists and
teach graduate students a variety of concepts in molecu-
lar profiling data analysis in a context of translational
bioinformatics [62].
G-DOC Plus hosts a number of well-known public
studies where the raw data was downloaded, processed
uniformly and then uploaded to our system, including
TCGA Ovarian cancer dataset, the 1000 genomes data-
set, the NCI-60 cell line collection, two studies from the
CaArray collection, the REMBRANDT study, and one
study from ImmPort. We have recently added five
pediatric cancer studies to G-DOC Plus, which help
researchers analyze individual molecular data types to
identify biomarkers. Hosting such well-known studies
allows for easy reproducibility of results. Such analyses
enables users to better understand molecular changes
that lead to disease or phenotype of interest.
G-DOC Plus has also been used as a resource for host-
ing public data. The clinical and multi-omics data from
this publication [40] has been made available to the
public through G-DOC Plus via the CRC_MADHA-
VAN_2013_01 study, and we hope to encourage owners
of other private datasets in making their data public
through our platform for wider access by the biomedical
research community.
Comparison of G-DOC Plus with similar tools
Three competing tools used for translational research in-
clude the cBio cancer genomics portal [55], TranSMART
[63] and Oncomine [56]. The cBio cancer genomics portal
is a free online tool that has processed data from many
cancer genomics studies including the TCGA collection.
TranSMART allows scientists to develop and refine re-
search hypotheses by investigating correlations between
phenotypic and omics data. Oncomine is another transla-
tional bioinformatics platform, but has limited functional-
ity and access to data in its freely available version. We
briefly summarized the differences between these tools
in Table 2. A comprehensive comparison of these
translational bioinformatics platforms including G-
DOC has been summarized in these papers [64–66].
Conclusions
The data and tools in G-DOC Plus have enabled multi-
modal inferences across cancer studies. We have lever-
aged this to support the detection of prognostic markers
for relapse in colorectal cancer samples; to detect key
metabolites related to disease severity; to identify pro-
gression and responsiveness to corticosteroid treatment
in children with DMD; and to examine breast cancer
MRI images for generating new research hypothesis.
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In the future, we plan to enable users to upload their
pre-processed data for multi-omics and NGS data ana-
lysis. We are planning to expand our data collection to
add more next generation sequencing studies, medical
imaging and non-cancer datasets. We also hope to add
features including allowing users to see gains and losses
in copy number, support for siRNA data, improved
enrichment analysis and visualizations using newer
technologies.
The long-term vision of G-DOC Plus is to extend this
translational bioinformatics platform to stay current with
emerging omics technologies and analysis methods to
continue supporting novel hypothesis generation, ana-
lysis and validation for integrative biomedical research.
By integrating several aspects of the disease and ex-
posing various data elements, such as outpatient lab
workup, pathology, radiology, current treatments, mo-
lecular signatures and expected outcomes over a web
interface, G-DOC Plus will continue to strengthen
precision medicine research.
Availability and requirements
 Project name: G-DOC Plus
 Project home page: https://gdoc.georgetown.edu
 Tutorials and demo video: https://gdoc.georgetown.
edu/tutorials
 Access: Any web browser, preferably Mozilla Firefox
3.5+ or Google Chrome
 Web browser requirements: Flash 10.0+, Java 1.6+
This requirement can be checked here: https://gdoc.
georgetown.edu/gdoc/home/requirementCheck
 Other information: G-DOC Plus is freely available
without restrictions to all users. Registration and
acceptance of terms of use are required before first
login.
Additional files
Additional file 1: Front page of G-DOC Plus showing total number of
studies, and samples in various disease types. (PNG 885 kb)
Additional file 2: What’s new in G-DOC Plus? (DOCX 87 kb)
Additional file 3: Screen shot of 1000 genomes use case with settings
for poor metabolizers. (PNG 133 kb)
Additional file 4: Screen shot of variant search use case with the settings.
(PNG 265 kb)
Additional file 5: Screen shot of G-DOC Plus showing clinical cohort
creation. (PNG 424 kb)
Additional file 6: T-test with FDR performed on gene expression data
Astrocytoma and GBM patients. Screen shot of results on G-DOC Plus to
show DEGs. (PNG 344 kb)
Additional file 7: Rembrandt T-test with CIN cytobands. (PNG 344 kb)
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